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Abstract
Introduction
Oxidative stress is one of many factors suspected to promote antinuclear autoantibody (ANA)
formation. Reactive oxygen species can induce changes in the antigenic structure of
macromolecules, causing the immune system to treat them as “neo-antigens” and start production of
autoantibodies. This study was designed to evaluate the relationship between oxidative stress
markers, lifestyle factors and the detection of ANA.
Material and methods
We examined measures of oxidative stress indices of free-radical damage to lipids and proteins,
such as total oxidant status (TOS), concentration of protein thiol groups (PSH), and malondialdehyde
(MDA), activity of superoxide dismutase (SOD) in in 1731 serum samples. The parameters of the non-
enzymatic antioxidant system, such as total antioxidant status (TAS) and uric acid concentration
(UA), were also measured and the oxidative stress index (OSI -index) was calculated. All samples
were tested for the presence of ANA using an indirect immunofluorescence assay (IIFA).
Results
The presence of ANA in women was associated with lower physical activity (p=0.036), less frequent
smoking (p=0.007) and drinking of alcohol (p=0.024) accompanied by significant changes in SOD
isoenzymes activity (p<0.001) and a higher uric acid (UA) concentration (p<0.001). In ANA positive
males we observed lower concentrations of PSH (p=0.046) and increased concentrations of MDA
(p=0.047).
Conclusions
The results indicate that local oxidative stress may be associated with increased probability of ANA
formation in a sex-specific manner.
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Introduction: Oxidative stress is one of many factors suspected to promote antinuclear autoantibody 
(ANA) formation. Reactive oxygen species can induce changes in the antigenic structure of 
macromolecules, causing the immune system to treat them as “neo-antigens” and start production of 
autoantibodies. This study was designed to evaluate the relationship between oxidative stress markers, 
lifestyle factors and the detection of ANA. 
Material and methods: We examined measures of oxidative stress indices of free-radical damage to 
lipids and proteins, such as total oxidant status (TOS), concentration of protein thiol groups (PSH), 
and malondialdehyde (MDA), activity of superoxide dismutase (SOD) in in 1731 serum samples. The 
parameters of the non-enzymatic antioxidant system, such as total antioxidant status (TAS) and uric 
acid concentration (UA), were also measured and the oxidative stress index (OSI -index) was 
calculated. All samples were tested for the presence of ANA using an indirect immunofluorescence 
assay (IIFA).  
Results: The presence of ANA in women was associated with lower physical activity (p=0.036), less 
frequent smoking (p=0.007) and drinking of alcohol (p=0.024) accompanied by significant changes in 
SOD isoenzymes activity (p<0.001) and a higher uric acid (UA) concentration (p<0.001). In ANA 
positive males we observed lower concentrations of PSH (p=0.046) and increased concentrations of 
MDA (p=0.047).  
Conclusions: The results indicate that local oxidative stress may be associated with increased 
probability of ANA formation in a sex-specific manner. 
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Nowadays, clinical investigations have spread across various areas of research fields [1,2]. 
Recently, clinical research has also considered the interesting topic of evaluating the role of oxidative 
stress (OS) in the development and progression of auto-immune diseases (ADs). Over 81 disorders are 
classified as AD and occur when an immune response to self-antigens results in damage or 
dysfunction to tissues [3]. ADs include a very diverse range of pathophysiological mechanisms and 
clinical consequences [3]. Regardless of the clinical picture, all ADs go through sequential phases of 
asymptomatic initiation and propagation, which may be accompanied by the presence of 
autoantibodies (AAb) [4]. AAb are a serological hallmark of AD and detection of AAb is often used to 
establish an early diagnosis in patients with clinical symptoms. However, AAb are often found in 
otherwise healthy individuals, but usually with low titers [5–7]. The etiology of AAb formation is not 
yet fully understood. There are many suspected factors that increase the risk of developing AAb 
including sex (more common in women) [6,8–10], genetic predisposition (most of the polymorphisms 
are located in regulatory regions of genes whose products are believed to play roles in immune 
responses) [4,11,12], defective removal of apoptotic cells [13–18] and various environmental factors 
such as infections [19,20], oxidative stress [21–26], physical and chemical agents [15,21,27–29], as 
well as stressful life events [30]. However, regardless of the initial cause, the development of 
autoimmunity always occurs when there is breakdown in the regulation of B-cell or T-cell activation 
threshold and abnormal survival of autoreactive lymphocytes [4,31–39].  
As mentioned above, one of the factors that may play a role in the development and course of 
AD is oxidative stress. Reactive oxygen species (ROS), present in acute or chronic OS, can lead to 
changes in the antigenic structure of macromolecules, causing the immune system to treat them as 
“neo-antigens” [16,32,35,40–45]. Because the antigens are products of oxidation, e.g. lipid 
peroxidation in the case of oxidized phospholipids (OxPL) and malondialdehyde-modified structures 
[46–48], or direct oxidative damage of proteins [49–51], we refer to them oxidation-specific epitopes 
(OSEs). In recent years it has become increasingly apparent that OSEs are recognized by the pattern 




remaining mechanisms of the innate immune system )molecular mimicry, epitope spreading and 
natural autoantibody (NAAb) production) play a pivotal role in the process of AAb formation 
[4,23,24,41,53]. For example Chou et al have shown that approximately 30% of all natural IgM 
antibodies, secreted by a subset of B1 cells target OSEs [44]. Epitope spreading (also epitope drift) is 
the spread of antigenicity from a given epitope to other parts of the protein or other proteins [41,43]. 
Thus, altered molecules, with sufficient homology to the native protein antigens, can result in the 
production of specific autoantibodies and lead to the development of AD[41,42,44,54–64]. Systemic 
autoimmune rheumatic diseases (SARDs) are an important group of ADs. According to current 
recommendations, when diagnosis of a SARD is suspected, the indirect immunofluorescence assay 
(IFA), using human epithelial larynx cancer cell line (HEp-2) as a substrate, is the gold standard 
screening test [65–70]. This approach determines the concentration of antinuclear antibodies (ANA) 
and the type of pattern staining. When high autoantibody titers are detected and are accompanied by 
clinical signs, connective tissue disease is very likely [70,71].  
Previous studies have shown that patients with clinical manifestations of SARD and high titers 
of ANA also have increased OS [41,72]. Recent research has demonstrated that several biomarkers of 
OS (such as malondialdehyde (MDA), a marker of lipid peroxidation) are found at higher levels in the 
blood of  systemic sclerosis (SSc) and rheumatoid arthritis (RA) patients than in controls [49,73,74]. 
Conversely, the concentration of protein thiol groups (PSH) and the activity of superoxide dismutase 
(SOD) have been shown to be decreased in RA, SSc and systemic lupus erythematosus (SLE) [74–80]. 
These observations are consistent with enhanced inflammation, initiated by an autoimmune response. 
However, it is not known whether the presence of autoantibodies, at  low titres is associated with 
changes in OS markers. Nor is it clear whether  OS contributes to AAb the formation. Therefore, this 
study was designed to evaluate the relationship between OS markers and the detection of ANA. 
Materials and methods 







A nationwide observational, cross-sectional study was carried out in Poland in the fourth 
quarter of 2015 and the first and second quarters of 2016. 
Sampling 
This study  is part of a large research program “Nationwide study of cardiovascular health in 
primary care in Poland - LIPIDOGRAM2015 and LIPIDOGEN2015”, the design and rationale of 
which have been described in detail previously by Jóźwiak et. Al [81]. Briefly, the recruitment was 
carried out by 438 primary care physicians in 16 major administrative regions of Poland. 
Physicians/investigators were randomly selected from the Medical Data Management database. The 
expected number of patients recruited for LIPIDOGRAM2015 study (consecutive samples) was 
13,000 - 14,000 with a random sample of 13 - 15% (1,700 – 2,000) enrolled to the LIPIDOGEN2015 
sub study. The program only covered adult patients over 18 years old. Each patient had to complete a 
questionnaire concerning their medical and family history, concomitant diseases and pharmacotherapy 
as well as lifestyle factors like alcohol consumption, tobacco smoking, physical activity and use of diet 
( i.e. hypolipemic, hypoglycaemic, hypotensive diets). The following criteria were used in the question 
on alcohol consumption: moderate drinkers - persons consuming alcohol at a rate of 1-2 units/day 
(women) or 1-3 units/day (men), with the following conversion factor applied: 1 unit = 10-15 g 
ethanol = 250 ml beer (glass) = 150 ml wine (glass) = 30 ml vodka (glass); heavy drinkers - people 
who consume alcohol in quantities greater than those assumed for moderate drinkers and persons who 
do not consume alcohol at all, or persons who consume alcohol occasionally in amounts significantly 
less than those assumed for persons with moderate alcohol consumption. The following criteria were 
used for the tobacco smoking question: smokers - those who had consistently smoked at least 1 
cigarette/week in the period preceding the survey; former smokers - those who had permanently given 
up smoking in at least the last 3 months preceding the survey; non-smokers - those who had never 
smoked a cigarette. The following criteria were used in the physical activity question: regular physical 
effort - increased activity of the musculoskeletal system, regularly for 2-2.5h/week, defined as 





household chores; or no regular physical activity - people who do not meet the criteria of regular 
physical activity; or others who did not provide detailed information on the level of their physical 
activity. In the question concerning the use of diet (hypolipemic, hypoglycaemic, hypotensive) the 
following criteria were used: Use of an appropriate diet - regular consumption of varied low 
cholesterol foods, moderate consumption of medium cholesterol foods, reduced consumption of 
saturated fats - in favor of monounsaturated and polyunsaturated fats, reduced consumption of 
carbohydrates and sweetened drinks, reduced consumption of table salt, increased consumption of 
fish, increased consumption of fruit and vegetables and fibre-rich foods or no use of an appropriate 
diet - those not meeting the criteria for following an appropriate diet. Anthropometric measurements 
(height, body weight, waist circumference, and hip circumference) were performed at the doctor’s 
office. For all enrolled patients, serum samples were obtained after ≥12 h of fasting. On the same day, 
measurements of blood pressure, heart rate, and fasting glucose were obtained together with the lipid 
profile. For the LIPIDOGEN2015 sub-study, saliva samples for DNA isolation and blood samples for 
measurement of glycated hemoglobin, oxidative stress parameters, autoantibody levels, and 
inflammatory cytokine and apolipoprotein profiles were collected.  
For this study we used 1731 serum samples from the abovementioned LIPIDOGEN2015 sub-
study. The tested group included 1043 women and 688 men. The blood samples were transferred in 
cooled containers (-20oC) to a central laboratory (Silesian Analytical Laboratories – SLA in Katowice, 
Poland) for biochemical analyses and then to the autoimmune laboratory (Euroimmun Poland Ltd. 
Customer Training Laboratory in Wroclaw, Poland) for ANA determination. 
Laboratory analyses 
Measurements of total cholesterol (TC), triglycerides (TG), high-density lipoprotein 
cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) (made with direct 
immunological measurement) were performed and carried out using the same methodology by the 
Siemens Advia 1800 analyser and Siemens reagents (Munich, Germany), within 12 h of obtaining the 




and Rightest strip tests (Taichung City, Taiwan). HbA1c was assessed using high-performance liquid 
chromatography (HPLC) performed by Variant II Turbo (Bio-Rad, Hercules, California, USA). 
To quantify the intensity of oxidative stress,  indices of free-radical damage to lipids and 
proteins, and enzymatic and non-enzymatic antioxidant system parameters in serum and erythrocytes 
were measured. In serum, indices of free-radical damage to lipids and proteins included: total oxidant 
status (TOS) [82], protein thiol groups (PSH) [83] and the concentration of malondialdehyde (MDA) 
[84].The activity of superoxide dismutase (SOD) [85] was determined in serum. In addition, 
parameters of non-enzymatic antioxidant system, such as total antioxidant capacity (TAC) [86] and the 
concentration of uric acid (UA) were also determined. The oxidative stress index (OSI-index) was 
defined as the ratio of the TOS level to TAS level. Specifically, OSI-index (arbitrary unit) = TOS 
(μmol H2O2 Eq/L)/TAS (μmol Trolox Eq/L)[82] 
ANA were detected using an indirect immunofluorescence assay (IFA) employing human 
laryngeal carcinoma cells (HEp-2) and commercially available Euroimmun Medizinische 
Labordiagnostika AG (Lübeck, Germany) test kits Mosaic Basic Profile 3 (catalogue number FC 
1800-2010-3).  Sample incubation was carried out manually, according to the manufacturer’s 
instructions, except for the fact that 998 samples were diluted with a threshold cut-off 1:160 as 
recommended by the current guidelines [68] and 733 patient samples were diluted with a threshold 
cut-off 1:100 as recommended by the test kit manufacturer's instructions. The samples were divided 
into two groups randomly. The results were evaluated on a EUROstar III fluorescence microscope 
(CarlZeiss Oberkochen, Germany). The test results included a qualitative assessment of the presence 
of ANA, estimation of antibody titer, and determination of the characteristic pattern according to the 
(ICAP) nomenclature [67]. The results of IFA were collected and stored as digital images.  
Statistical analysis 
Statistical analyses were performed using Statistica 13.3 (StatSoft, Tulsa, USA). Data are 
expressed as mean ± SD (normal distribution) and as median and range (nonparametric distribution) 





markers related to autoimmune diseases according to clinical variables was performed using the 
Mann-Whitney-U test for nonparametric variables or the χ2 test/Fisher exact tests where appropriate. 
A two-sided p<0.05 was considered to indicate statistical significance. 
Ethical approval 
The study was performed in accordance with the principals outlined in Declaration of Helsinki[87]. 
Every patient gave a written informed consent to participate. The study was approved by the 
Bioethical Committee of the Chamber of Physicians (No.K.B.Cz.-0018/2015). 
Results 
The study included 1731 patients attending primary health care practices (1043 women and 
688 men). 1098 people were diagnosed with hypertension, coronary artery disease, dyslipidemia, 
diabetes, atrial fibrillation, kidney disease or stroke. 649 people were apparently healthy individuals. 
The mean age of participants was 51 ± (SD 13 years) and 60.25% were female (Table 1). The body 
mass index (BMI) indicated that the participants were on average  slightly overweight [88], and the 
average waist-hip ratio (WHR) was above the normal range for both men and women [89]. 
The ANA test was positive in 260 patients (15.0% of the entire study population). A total of 
201 patients had antibody titers determined at screening levels of 1:100 (n=116) or 1:160 (n=85). Only 
59 patients had ANA titer higher than the cut-off threshold (1:100 or 1:160). 
The study cohort was analysed to explore associations between lifestyle factors, lifestyle 
diseases and the occurrence of ANA. It was found that ANA are more frequently detected in women 
(71.9% vs. 28.1% p<0.001) than in men. The results presented in Table 2 show that the  occurrence of 
ANA in women is associated with lower physical activity (p=0.036), less frequent smoking (p=0.007) 
and low alcohol consumption (p=0.024). In case of men, none of the lifestyle-related aspects analyzed  
were associated with the presence of ANA. Lifestyle diseases were not associated with the presence of 




The analysis of the association between oxidative stress markers and the occurrence of ANA 
by sex of the subjects showed that ANA positive men had a significant 6% decrease in PSH 
concentration (p=0.046) and an 11% increase in MDA concentration (p=0.047) compared with ANA 
negative men. In the ANA positive women, on the other hand, changes in the activity of SOD 
isoenzymes were observed (6% increase in MnSOD activity (p=0.001) and 8% decrease in CuZnSOD 
activity (p<0.001)). Moreover, in ANA positive women, the concentration of UA was 10% higher than 
in women without these AAbs. The results for individual parameters are presented in Table 3. 
We also investigated whether the specific pattern types in ANA positive patients differ in 
relation to sociodemographic parameters and markers of oxidative stress. For most ANA patterns, no 
significant differences were observed. However,  several observations warrant further investigation. In 
particular, AC-2 positive samples showed a 7% lower activity of the CuZnSOD isoenzyme (p=0.044), 
a 5% lower concentration of UA (p=0.035) and a lower TAC (p=0.007) compared with the other ANA 
positive samples. Autoantibodies associated with the AC-21 pattern were observed more commonly in 
individuals with less physical activity (p=0.005), diagnosed coronary artery disease (p=0.013), 
previous myocardial infarction (p=0.049) or dyslipidemia (p=0.032) than in other ANA positive 
patients. In AC-21 samples, a lower concentration of PSH was also observed (p=0.038). In men, the 
AC9/AC10 pattern was very common (p<0.001) and the AC4/AC5 pattern was much less common 
(p=0.027) compared to other ANA positive patients. In patients displaying the AC4/AC5 pattern, a 
lower intensity of oxidative stress (a 32%  lower OSI-index) was observed compared with other ANA 
positive patients (p=0.023). All the selected parameters for which significant differences were 
observed, are presented in Table 4 and Table 5. 
Discussion 
The observed relationships between some markers of oxidative stress, and ANAs supports the 
hypothesis that oxidative stress may be associated with an increased likelihood of ANA formation. It 
is possible that oxidative stress, and the associated increase in ROS levels may initiate the formation 




oxidative stress in cells or tissues which has subsequently resolved. Hence we observed changes 
indicative of an increase in oxidative stress for only some markers.  
The aim of this study was to determine whether there is an association between OS  and the 
presence of ANA. However the data collected from participants additionally allowed us to assess 
whether the lifestyle factors or the lifestyle diseases affecting patients are associated with the presence 
of ANA. We detected ANA in 15.02% of the tested samples. This result is similar to the results 
obtained by others using  similar cut-off thresholds [68,90]. Moreover, ANA were more frequently 
detected in women  (71.9%, p<0.001), therefore in subsequent analyses we took the influence of sex 
into account. 
In the Polish population, the prevalence of the diseases of civilisation, such as cardiovascular 
diseases (CVD) and often related lipid disorders, is high, and many different risk factors related to 
patients' lifestyles are responsible for their development [91,92]. The data presented in Table 2 show 
that that the occurrence of lifestyle diseases is not associated with an increased  probability of 
developing ANA, even when sex differences are taken into account. This finding agrees with the lack 
of association between ANA and selected cardiovascular and metabolic diseases observed in a German 
population [8]. In addition, studies conducted in Japan found no association between BMI, diabetes, 
hypertension and the presence of ANA [93].  However, we note that for some autoantibodies, e.g. 
those resulting in the AC-21 pattern, there may be exceptions to this rule, as will be discussed later. 
We also observed that individuals who declared regular physical activity were less likely to show 
positive ANA (p=0.025). This observation supports the thesis, that physical activity is beneficial to the 
maintenance of health, and that the health benefits of exercise may extend to reducing the risk of 
autoantibody formation and the subsequent development of autoimmune diseases. 
Surprisingly, in our cohort, women who declared cigarette smoking and alcohol drinking were 
less likely to have ANA (p=0.007 and p=0.024 respectively) which stands in contrast to the fact that 
many studies have shown a linkage between smoking and the increased likelihood of autoimmune 
diseases, such as rheumatoid arthritis (RA), multiple sclerosis (MS), and systemic lupus erythematosus 





of women than in the group of men, and that  women are more likely to have autoantibodies, such a 
surprising result may be the effect of an unfavorable combination of these two factors.  
In the present study, more than three-quarters of ANA positive samples had a low antibody 
titer, around the cut-off level. Nevertheless, in the group of ANA positive men, a significantly lower 
PSH concentration and a higher MDA concentration was observed. In the case of ANA positive 
woman, higher UA levels and small differences in  the activity of SOD isoenzymes were observed. 
These phenomena may support the thesis outlined in the introduction that local OS and oxidative 
specific epitopes (OES) formed under such conditions may play a role in the formation of 
autoantibodies. Interestingly, no significant changes in global OS markers such as TAC, TOS and 
OSI-index were observed in the study group, which may indicate the lack of active inflammatory 
process caused by the presence of ANA. Therefore, we cannot exclude the possibility that the 
observed differences only seen in  some parameters of OS may indicate its local character, or may be 
remnants of a recently resolved increase in OS. In addition, some researchers have suggested that 
autoantibodies may be produced as a result of locally increased OS leading to cell death by apoptosis 
or necrosis [18,99,100]. If this is the case, the immune mechanisms involved in the production of 
autoantibodies might play a role in the removal of protein fragments cleaved from residues formed 
during cell death and tissue damage [101]. It is important to bear in mind that the development of 
autoimmune responses is a long-term process. It may take some time from the occurrence of an 
episode of increased OS and elevated ROS to result in formation of neo-antigens and for immune 
tolerance to these altered autoantigens to be lost, such that the production of autoantibodies is initiated. 
Since mitochondria are one of the main sources of ROS in the body, we were interested to 
look for associations between antimitochondrial antibodies (AMA) (AC-21 pattern) and the activity of 
SOD isoenzymes. It is known that the mitochondrial matrix predominantly contains the manganese 
isoform of superoxide dismutase (MnSOD) [102,103].  Our hypothesis were not confirmed. Lower 
PSH levels were observed in patients with the AC-21 pattern, but this was not associated with an 
increased antioxidant activity of SOD in the mitochondrial matrix, compared with other ANA positive 





this time, but the lower PSH concentrations suggest that such an event may have occurred in the recent 
past. Second, it was noticed that autoantibodies associated with the AC-21 pattern type  were much 
less frequent in the group of physically active people (p=0.005) and at the same time were more 
frequently observed in people suffering from coronary artery disease (p=0.013), myocardial infarction 
(p=0.049) and dyslipidemia (p=0.032). A healthy lifestyle seems to be associated with a lower 
likelihood of developing these autoantibodies.  
Surprising results were obtained for the AC-2 pattern type. These antibodies were more 
frequent in patients where particular OS markers such as TAC, CuZnSOD activity and UA had lower 
values than in other ANA positive patients. The lower TAC is most likely due to a decrease in UA 
concentration. Could it be that OS has no effect on the formation of these autoantibodies? 
Interestingly, this type of staining pattern was the most frequently detected type in our study (50% of 
all ANA positive samples). AC-2 is associated with antibodies recognizing the stress oncoprotein lens 
epithelium-derived growth factor p75 (LEDGF/p75), also known as dense fine speckled 70kDa 
(DFS70) autoantigen. Its clinical significance has not yet been established, but it occurs in apparently 
healthy individuals and is therefore considered a marker to exclude SARD [104]. This finding has 
inspired our group to perform further research in this direction, in which we intend to investigate the 
relationship between oxidative stress and anti DFS-70 antibodies.  
Limitation 
The present study is limited by the lack of data about the clinical symptoms of SARDs among 
the participants. So we could not compare the results obtained with any clinical manifestations. This 
information would allow a better analysis of the real relationship between the detected autoantibodies, 
OS and lifestyle factors. It may be that the lifestyle of patients in whom the presence of ANA is 
accompanied by a clinical manifestation of an autoimmune disease differs significantly from 
asymptomatic individuals. Moreover, chronic inflammation, often associated with SARD, may cause 






The observed changes in some oxidative stress markers, in particular an increase in MDA 
concentration and a decrease in PSH concentration supports the hypothesis that local OS may be 
associated with a higher probability of ANA formation. At the same time, our data indicate that 
changes in individual OS markers and their association with ANA are sex-dependent and may only 
involve some antinuclear autoantibodies. In conclusion, we believe that there is an urgent need for 
further and more precise research in the field of OS as a trigger, modulator and driver of autoimmune 
processes. It remains to be clarified which specific autoantibodies are affected by OS and which are 
not. However, it seems likely that physical activity reduces the likelihood of autoantibody formation. 
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Mean SD Mean SD Mean SD 
Age 51.0 13.0 50.4 13.1 51.6 12.9 
Height (cm) 168 9.15 177 6.71 163 6.05 
Weight (kg) 80.2 17.1 91.2 15.2 73.0 14.1 
BMI (kg/cm2) 28.2 5.05 29.3 4.50 27.5 5.29 
Waist circumference (cm) 94 14.3 101 12.0 89.3 13.6 
Hip circumference (cm) 105 10.8 105 9.33 105 11.7 
WHR 0.89 0.09 0.96 0.07 0.85 0.07 






Table 2. The occurrence of ANA in relation to lifestyle factors. 




















 % n % n p-value % n % n p-value % n % n p-value 
Sex (% of men) 41.8% 615 28.1% 73 <0.001           
Physical activity  
(use of regular physical effort) 
44.8% 659 37.3% 97 0.025 47.2% 290 43.8% 32 0.592 43.1% 369 34.8% 65 0.036 
Dietary habits  
(use of an appropriate diet) 
67.4% 992 63.8% 166 0.257 72.4% 445 67.1% 49 0.348 63.9% 547 62.6% 117 0.731 
Tobacco Smoking  
(current smokers) 
65.2% 959 49.2% 128 0.001 76.9% 473 71.2% 52 0.531 56.8% 486 40.6% 76 0.007 
Alcohol consumption (moderate or 
heavy drinkers)  
16.9% 249 11.2% 29 0.019 18.0% 111 15.1% 11 0.529 16.1% 138 9.6% 18 0.024 
Chronic kidney disease 2.7% 40 1.5% 4 0.265 2.3% 14 1.4% 1 0.617 3.0% 26 1.6% 3 0.281 





Myocardial infarction 4.1% 61 4.2% 11 0.950 7.6% 47 8.2% 6 0.862 1.6% 14 2.7% 5 0.337 
Ischemic stroke 1.5% 22 1.9% 5 0.608 2.1% 13 1.4% 1 0.671 1.1% 9 2.1% 4 0.225 
Haemorrhagic stroke 0.3% 4 0.4% 1 0.755 0.3% 2 1.4% 1 0.201 0.2% 2 0.0% 0 0.509 
Atrial fibrillation 2.8% 41 4.2% 11 0.209 2.6% 16 4.1% 3 0.458 2.9% 25 4.3% 8 0.337 
Dyslipidemia 49.4% 726 51.9% 135 0.445 54.8% 337 60.3% 44 0.374 45.4% 389 48.7% 91 0.424 
Family hypercholesterolemia 3.7% 55 2.3% 6 0.249 3.6% 22 4.1% 3 0.819 3.9% 33 1.6% 3 0.127 
Diabetes mellitus 15.6% 229 19.2% 50 0.139 19.5% 120 26.0% 19 0.190 12.7% 109 16.6% 31 0.163 
Arterial hypertension 42.1% 619 47.7% 124 0.092 47.8% 294 56.2% 41 0.177 38.0% 325 44.4% 83 0.103 
Healthy individuals 36.3% 534 38.1% 99 0.584 30.9% 190 27.4% 20 0.540 40.2% 344 42.2% 79 0.604 







Table 3. Levels of oxidative stress markers in ANA positive and negative individuals. 
















 Mean SD Mean SD 
% 
change 




Glucose (mg/dl) 107.4 29.56 113.0 32.42 5.1% 0.136 101.3 24.09 106.6 29.42 5.2% 0.009 
HbA1c (%) 5.76 1.03 6.05 1.39 5% 0.031 5.65 0.88 5.73 0.99 1% 0.279 
TC (mg/dl) 200.8 43.6 208.7 57.3 4% 0.157 210.1 44.6 209.0 47.0 -1% 0.771 
HDL (mg/dl) 47.3 12.8 46.1 11.6 -3% 0.451 60.5 15.4 58.8 16.2 -3% 0.153 
TG (mg/dl) 190.3 163.1 205.6 189.9 8% 0.458 137.3 124.5 132.0 77.1 -4% 0.576 
LDL (mg/dl) 128.2 40.1 133.0 46.1 4% 0.341 132.8 42.4 134.7 46.4 1% 0.585 
PSH (µmol/g protein) 3.95 1.18 3.70 1.00 -6% 0.046 3.66 1.09 3.68 1.21 0% 0.846 
TAC (mmol/l)  1.15 0.28 1.11 0.23 -4% 0.226 1.06 0.26 1.06 0.27 0% 0.845 
TOS (µmol/l) 7.47 6.54 6.61 4.57 -12% 0.273 6.76 7.09 6.82 5.59 1% 0.926 
OSI-index (arbitrary units) 0.71 0.76 0.63 0.46 -11% 0.405 0.71 0.87 0.70 0.80 -1% 0.922 
SOD (NU/ml) 19.64 2.82 19.58 3.36 0% 0.861 20.22 2.95 20.02 2.43 -1% 0.391 
MnSOD (NU/ml) 10.06 2.48 10.16 2.67 1% 0.735 10.24 2.32 10.85 2.55 6% 0.001 
CuZnSOD (NU/ml) 9.61 2.77 9.44 3.13 -2% 0.628 9.99 2.91 9.16 2.39 -8% <0.001 
MDA (µmol/l) 3.01 1.35 3.35 1.51 11% 0.047 2.92 1.30 3.05 1.31 5% 0.212 
UA (µmol/l) 415 107 389 100 -6% 0.107 328 95 360 98 10% <0.001 
ANA – anti-nuclear antibody, HbA1c – Hemoglobin A1c, HDL - high-density lipoprotein cholesterol, 
LDL – low-density lipoprotein cholesterol, MDA – malondialdehyde, OSI-index – oxidative stress 
index, PSH – protein thiol groups, SOD – superoxide dismutase, TAC – total antioxidant capacity, TC 





Table 4. The relationship between selected lifestyle factors and ANA pattern staining. 
  ANA positive 
  
AC 2 (-) AC 2 (+) 
 
AC 21 (-) AC 21 (+) 
 
AC4/AC5 (-) AC4/AC5 (+) 
 
AC9/AC10 (-) AC9/AC10 (+) 
 
n=130 n=130 n=220 n=40 n=222 n=38 n=232 n=28 
  % n % n p-value % n % n p-value % n % n p-value % n % n p-value 
Sex (% of men) 33.10% 43 23.10% 30 0.073 28.20% 62 27.50% 11 0.929 30.60% 68 13.20% 5 0.027 24.10% 56 60.70% 17 <0.001 
Physical 
activity 
35.40% 46 39.20% 51 0.523 40.90% 90 17.50% 7 0.005 36.50% 81 42.10% 16 0.51 36.20% 84 46.40% 13 0.915 
Coronary 
artery disease 
11.50% 15 10.80% 14 0.845 9.10% 20 22.50% 9 0.013 12.20% 27 5.30% 2 0.213 11.60% 27 7.10% 2 0.486 
Myocardial 
infarction 
4.60% 6 3.80% 5 0.759 3.20% 7 10.00% 4 0.049 5.00% 11 0.00% 0 0.162 4.30% 10 3.60% 1 0.477 
Dyslipidemia 57.70% 75 46.20% 60 0.063 49.10% 
10
8 
67.50% 27 0.032 53.60% 
11
9 
42.10% 16 0.191 50.00% 116 67.90% 19 0.42 
Healthy 
individuals 
33.80% 44 42.30% 55 0.161 40.50% 89 25.00% 10 0.064 37.40% 83 42.10% 16 0.582 39.70% 92 25.00% 7 0.797 






Table 5. The relationship between oxidative stress markers and ANA pattern staining. 
  ANA positive 
  
AC 2 (-) AC 2 (+) 
  







AC9/AC10 (-) AC9/AC10 (+) 
                  
n=130 n=130 n=220 n=40 n=222 n=38 n=232 n=28 




















Age 54.7 12.3 52.8 12.6 -4% 0.211 53 12.7 57.6 10.3 9% 0.033 54.2 12.5 51.2 12 -6% 0.173 53.8 12.5 53.5 12.3 0% 0.915 
BMI 27.5 5.07 28.5 5.12 3.70% 0.111 27.83 4.78 28.97 6.61 4.10% 0.195 28.4 5.16 26.02 4.37 
-
8.20% 




PSH (µmol/g protein) 3.72 1.13 3.65 1.18 -2% 0.613 3.75 1.18 3.34 0.94 -11% 0.038 3.64 1.14 3.94 1.23 8% 0.131 0.7 0.75 0.55 0.36 -22% 0.291 
TAC (mmol/l)  1.12 0.25 1.03 0.26 -8% 0.007 1.06 0.27 1.14 0.22 7% 0.086 1.07 0.26 1.13 0.28 6% 0.163 10.6 2.6 10.8 2.61 2% 0.755 
OSI-index (arbitrary unit) 0.61 0.52 0.76 0.87 25% 0.092 0.67 0.74 0.75 0.63 12% 0.509 0.72 0.75 0.49 0.45 -32% 0.023 3.12 1.38 3.25 1.34 4% 0.651 
SOD (NU/ml) 20.1 2.75 19.7 2.69 -2% 0.228 19.81 2.74 20.4 2.58 3% 0.203 20 2.66 19.5 3.07 -2% 0.332 3.66 1.14 3.87 1.25 6% 0.369 
MnSOD (NU/ml) 10.52 2.52 10.8 2.68 3% 0.405 10.63 2.56 10.84 2.85 2% 0.643 10.8 2.64 10.1 2.29 -6% 0.144 32.3 10.8 30.9 9.57 -4% 0.503 
CuZnSOD (NU/ml) 9.57 2.71 8.91 2.48 -7% 0.044 9.18 2.68 9.57 2.25 4% 0.388 9.21 2.53 9.41 3.09 2% 0.662 1.08 0.26 1.06 0.28 -2% 0.719 
UA (µmol/l) 377 87 359 110 -5% 0.035 363 97 395 105 9% 0.064 368 98 370 104 1% 0.866 367 101 377 83.4 3% 0.636 
AC – anti-cell, ANA – anti-nuclear antibody, BMI – body mass index, OSI-index – oxidative stress index, PSH – protein thiol groups, SOD – superoxide 






Figure 1. Research procedural stages
Powered by TCPDF (www.tcpdf.org)
Pr
ep
rin
t
